Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics
- PMID: 16215281
- DOI: 10.1385/MN:32:2:173
Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics
Abstract
Bipolar disorder is a devastating disease with a lifetime incidence of about 1% in the general population. Suicide is the cause of death in 10 to 15% of patients and in addition to suicide, mood disorders are associated with many other harmful health effects. Mood stabilizers are medications used to treat bipolar disorder. In addition to their therapeutic effects for the treatment of acute manic episodes, mood stabilizers are useful as prophylaxis against future episodes and as adjunctive antidepressant medications. The most established and investigated mood-stabilizing drugs are lithium and valproate but other anticonvulsants (such as carbamazepine and lamotrigine) and antipsychotics are also considered as mood stabilizers. Despite the efficacy of these diverse medications, their mechanisms of action remain, to a great extent, unknown. Lithium's inhibition of some enzymes, such as inositol monophosphatase and glycogen synthase kinase-3, probably results in its mood-stabilizing effects. Valproate may share its anticonvulsant target with its mood-stabilizing target or may act through other mechanisms. It has been shown that lithium, valproate, and/or carbamazepine regulate numerous factors involved in cell survival pathways, including cyclic adenine monophospate response element-binding protein, brain-derived neurotrophic factor, bcl-2, and mitogen-activated protein kinases. These drugs have been suggested to have neurotrophic and neuroprotective properties that ameliorate impairments of cellular plasticity and resilience underlying the pathophysiology of mood disorders. This article also discusses approaches to develop novel treatments specifically for bipolar disorder.
Similar articles
-
Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.Psychopharmacol Bull. 2001 Spring;35(2):5-49. Psychopharmacol Bull. 2001. PMID: 12397885 Review.
-
PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.Mol Psychiatry. 2002;7 Suppl 1:S46-56. doi: 10.1038/sj.mp.4001018. Mol Psychiatry. 2002. PMID: 11986995 Review.
-
Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.Acta Psychiatr Scand. 2012 Nov;126(5):332-41. doi: 10.1111/j.1600-0447.2012.01889.x. Epub 2012 Jun 8. Acta Psychiatr Scand. 2012. PMID: 22676371 Free PMC article. Review.
-
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.J Clin Psychiatry. 1999;60 Suppl 2:27-39; discussion 40-1, 113-6. J Clin Psychiatry. 1999. PMID: 10073385 Review.
-
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder.Biol Psychiatry. 2006 Jun 15;59(12):1160-71. doi: 10.1016/j.biopsych.2005.11.004. Epub 2006 Feb 2. Biol Psychiatry. 2006. PMID: 16457783 Review.
Cited by
-
DISC1 Pathway in Brain Development: Exploring Therapeutic Targets for Major Psychiatric Disorders.Front Psychiatry. 2012 Mar 22;3:25. doi: 10.3389/fpsyt.2012.00025. eCollection 2012. Front Psychiatry. 2012. PMID: 22461775 Free PMC article.
-
Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder.Semin Cell Dev Biol. 2011 Feb;22(1):105-13. doi: 10.1016/j.semcdb.2010.11.002. Epub 2010 Nov 18. Semin Cell Dev Biol. 2011. PMID: 21093602 Free PMC article. Review.
-
Target identification for CNS diseases by transcriptional profiling.Neuropsychopharmacology. 2009 Jan;34(1):18-54. doi: 10.1038/npp.2008.172. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923405 Free PMC article. Review.
-
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.Neuropsychiatr Dis Treat. 2016 Jul 11;12:1687-703. doi: 10.2147/NDT.S106479. eCollection 2016. Neuropsychiatr Dis Treat. 2016. PMID: 27468233 Free PMC article. Review.
-
Heritability and Familiality of Temperament and Character Dimensions in Korean Families with Schizophrenic Linkage Disequilibrium.Clin Psychopharmacol Neurosci. 2016 May 31;14(2):203-9. doi: 10.9758/cpn.2016.14.2.203. Clin Psychopharmacol Neurosci. 2016. PMID: 27121432 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical